AB0128 DIFFERENTIAL EXPRESSION OF PROTEINS IN PATIENTS WITH SUSPECTED SJÖGREN’S SYNDROME

Background Sjögren’s Syndrome (SS) is a chronic systemic autoimmune disease characterized by involvement of the exocrine glands in addition to wide spectrum manifestations. At present, conventional biomarkers do not respond unresolved needs regarding diagnosis, stratification phenotypes and appropriate effective therapies [1] . SS an orphan new could constitute potential future therapeutic targets [2] Objectives The purpose this study was carry out exploratory analysis six serum saliva samples from suspected patients identify protein distinguish who were diagnosed with those not. Methods We selected cohort 199 consecutive attended rheumatology department for SS: 3 met classification criteria 2002 and/or 2016 rheumatologist did meet finally diagnosed. Serum collected centrifuged at 1800g, divided into aliquots stored -80ºC. Saliva cold prevent degradation proteins, 1800g 4ºC A semiquantitative expression performed using “Proteome Profiler Human XL Cytokine Array Kit” arrays R&D system that detects 105 proteins containing interleukins, chemokines, inflammatory factors other soluble proteins. Analytes optical densities quantified Image J software. content analytes compared between non-SS unpaired Student´s t test measure odds analyte happening one group same another (OR: ratio) shown. Statistical Microsoft Excel P values ≤0.05 defined as significant 0.1< > 0.05 considered borderline. Results found increased levels CD14 (OR:1.21; =0.033), EGF (OR:1.18; =0.050), IP-10 1.23; =0.090) Pentraxin (OR:1.32; =0.095) VEGF (OR:1.41; =0.091) criteria, diagnosed, although only case EGF, statistical significance reached. In samples, we significantly ICAM1 1.67; =0.019), IL-6 (OR:1.20; =0.042) IL-19 (OR:1.51; =0.039) patient criteria. did. Conclusion syndrome presented higher serum, well decreased ICAM1, IL-6, saliva, when It necessary confirm these results larger patients. References [1]V.C. Pezoulas et al Computational Structural Biotechnology Journal ; 2022;20:471–484. [2]V. Manfrè syndrome: year review 2022. Clin Exp Rheumatol; 2022; 40: 2211-2224. Acknowledgements To all have participated study. Disclosure Interests None Declared.